BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 25.19 Million EUR | 292.23% |
| 2022 | 6.42 Million EUR | -67.79% |
| 2021 | 19.94 Million EUR | -27.01% |
| 2020 | 27.32 Million EUR | 10.27% |
| 2019 | 24.77 Million EUR | -2.28% |
| 2018 | 25.35 Million EUR | 209.9% |
| 2017 | 8.18 Million EUR | 31.08% |
| 2016 | 6.24 Million EUR | -56.21% |
| 2015 | 14.25 Million EUR | 388.83% |
| 2014 | 2.91 Million EUR | 5.13% |
| 2013 | 2.77 Million EUR | -13.47% |
| 2012 | 3.2 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 33.8 Million EUR | 0.0% |
| 2024 Q1 | - EUR | 0.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q4 | 25.19 Million EUR | 0.0% |
| 2023 FY | 25.19 Million EUR | 292.23% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 17.67 Million EUR | 0.0% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 24.71 Million EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 6.42 Million EUR | -67.79% |
| 2022 Q4 | 6.42 Million EUR | 0.0% |
| 2021 FY | 19.94 Million EUR | -27.01% |
| 2021 Q2 | -694 Thousand EUR | 0.0% |
| 2021 Q3 | - EUR | 100.0% |
| 2021 Q4 | 19.94 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 Q2 | 30.9 Million EUR | 0.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q4 | 27.32 Million EUR | 0.0% |
| 2020 FY | 27.32 Million EUR | 10.27% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 FY | 24.77 Million EUR | -2.28% |
| 2019 Q4 | 24.77 Million EUR | 0.0% |
| 2019 Q2 | 24.3 Million EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q4 | 25.35 Million EUR | 0.0% |
| 2018 FY | 25.35 Million EUR | 209.9% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q2 | 22.43 Million EUR | 0.0% |
| 2017 FY | 8.18 Million EUR | 31.08% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 Q2 | 7.43 Million EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 8.18 Million EUR | 0.0% |
| 2016 FY | 6.24 Million EUR | -56.21% |
| 2016 Q4 | 6.24 Million EUR | 0.0% |
| 2016 Q2 | 8.48 Million EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 Q3 | - EUR | -100.0% |
| 2015 Q4 | 14.25 Million EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 FY | 14.25 Million EUR | 388.83% |
| 2014 FY | 2.91 Million EUR | 5.13% |
| 2013 FY | 2.77 Million EUR | -13.47% |
| 2012 FY | 3.2 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | 86.81% |
| CureVac N.V. | 36.81 Million EUR | 31.576% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 93.323% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 93.323% |
| Formycon AG | 7.81 Million EUR | -222.367% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -35681.953% |
| Medigene AG | 2.03 Million EUR | -1137.377% |